Clinical trial NCT04639362: CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.
Official title: First Line Treatment With VeNEtoclaX and ibruTinib Induction Followed by Obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients Not in Complete Remission and/or With Detectable Bone Marrow Minimal Residual Disease (NEXT STEP Trial)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: CLL
Lead sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
Sponsor class: OTHER
Collaborators: name: Nordic Lymphoma Group
First posted: 2020-11-20
Enrollment: 85
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: FACTORIAL
Intervention model description: After 15 to 16 cycles of treatment the PI will assign patients to either observation (no further treatment) or intensification (treatment with ibrutinib and obinutuzumab), based on MRD results.
Primary purpose: TREATMENT

Brief summary: A recent study showed that 6 cycles of obinutuzumab when given after at least 1 year of ibrutinib did result in MRD conversion in a significant proportion of patients (50%). The precise influence, timing and interplay of venetoclax, ibrutinib and obinutuzumab on clearance of CLL cells in different compartments (PB, BM, LN), and achievement of uMRD and complete remission (CR) are not well known.

Therefore, the investigators set out a study to evaluate whether patients who are not in CR or who have detectable MRD after 12 months of combination treatment with ibrutinib and venetoclax (15 months total treatment including three months ibrutinib lead-in) could be converted into uMRD CR with an additional 6 cycles obinutuzumab in combination with ibrutinib.

Detailed description: The BCL-2 antagonist venetoclax, specifically if combined with a CD20 antibody proved highly active in clearance of chronic lymphocytic leukemia (CLL) cells in peripheral blood (PB) and bone marrow (BM) but less so in lymph nodes (LN), probably due to the abundant expression of additional anti-apoptotic proteins within the LN compartment. The investigators hypothesize that due to the forced egress from the LN by ibrutinib, leukemic cells cannot escape from the apoptosis initiating effects of venetoclax, making combination of these drugs highly effective. Preliminary data from multiple ongoing trials on this combination are indeed promising, with not only superior rates of undetectable minimal residual disease (uMRD) than other ibrutinib combinations but perhaps more important, achievement of complete LN responses in the majority of patients. Yet, also with this combination, a significant subgroup of patients are expected to remain with detectable MRD. A recent study showed that 6 cycles of obinutuzumab when given after at least 1 year of ibrutinib did result in MRD conversion in a significant proportion of patients (50%). The precise influence, timing and interplay of venetoclax, ibrutinib and obinutuzumab on clearance of CLL cells in different compartments (PB, BM, LN), and achievement of uMRD and complete remission (CR) are not well known.

Therefore, the investigators set out a study to evaluate whether patients who are not in CR or who have detectable MRD after 12 months of combination treatment with ibrutinib and venetoclax (15 months total treatment including three months ibrutinib lead-in) could be converted into uMRD CR with an additional 6 cycles obinutuzumab in combination with ibrutinib. In addition to efficacy, as measured by undetectable MRD rate, emphasis of this trial will be on clearance of different compartments (PB, BM, LN) at different time points on protocol and in follow up. In addition, the toxicity profile is taken into consideration.

Eligibility criteria: Inclusion Criteria:

* Documented CLL or SLL requiring treatment according to IWCLL criteria33, including minimal required markers (CD5/CD19/CD23 triple positive with light chain restriction);
* WHO performance status 0-3 (appendix C), stage 3 only if attributable to CLL/SLL;
* No prior treatment for CLL/SLL;
* Age at least 18 years;
* Adequate BM function defined as:

  * Hb \> 5 mmol/l or Hb \> 8 g/dL
  * Absolute neutrophil count (ANC) ≥ 0.75 x 109/L or 750/μL
  * Platelet count ≥ 50 x 109/L or 50,000 /μL Unless directly attributable to CLL/SLL infiltration of the BM, proven by BM biopsy;
* Estimated Glomerular Filtration Rate (eGFR) (MDRD) or estimated creatinine clearance (CrCl) ≥ 30ml/min (Cockcroft-Gault appendix E); Please note: in case eGFR or CrCl is \<50ml/min the patient needs to be considered high risk for TLS
* Adequate liver function as indicated:

  * Serum aspartate transaminase (ASAT) and alanine transaminase (ALAT) ≤ 3.0 x upper limit of normal (ULN)
  * Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of nonhepatic origin);
* Prothrombin time (PT)/International normal ratio (INR) \<1.5 x ULN and activated partial thromboplastin time (aPTT) \<1.5 x ULN;
* Negative serological testing for hepatitis B virus (Hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (anti-HBc) negative) and hepatitis C virus (hepatitis C antibody). Subjects who are positive for hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody must have a negative PCR result before enrollment. Those who are PCR positive will be excluded;
* Ability and willingness to adhere to the study visit schedule and other protocol requirements;
* Patient is capable of giving informed consent;
* Written informed consent.

Exclusion Criteria:

* Transformation of CLL (Richter's transformation);
* Malignancies other than CLL/SLL currently requiring systemic therapy or not being treated in curative intention or showing signs of progression after curative treatment;
* Patient with CNS involvement
* Known allergy to xanthine oxidase inhibitors and/or rasburicase;
* Intolerance of exogenous protein administration;
* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies. Known sensitivity or allergy to murine products;
* Active fungal, bacterial, and/or viral infection that requires systemic therapy; Please note: active controlled as well as chronic/recurrent infections are at risk of reactivation/infection during treatment (see section 9.2.3.1);
* Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled: infection, auto-immune hemolysis, immune thrombocytopenia, diabetes, hypertension, hyperthyroidism or hypothyroidism etc.);
* Patients known to be HIV-positive;
* Patient requiring treatment with a strong cytochrome P450 (CYP) 3A inhibitor (see appendix K) or anticoagulant therapy with warfarin or phenprocoumon n or other vitamin K antagonists; Please note: Patients being treated with DOACs apixaban, edoxaban or rivaroxaban can be included, but must be properly informed about the potential risk of bleeding under treatment with ibrutinib. Treatment with dabigatran should be avoided, due to risk of toxicity based on P-gp substrate (see appendix K)
* History of stroke or intracranial hemorrhage within 6 months prior to registration;
* Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease) (CTCAE grade III-IV, see appendix D);
* Severe pulmonary dysfunction (CTCAE grade III-IV, see appendix D);
* Patient with Child Pugh C
* Severe neurological or psychiatric disease (CTCAE grade III-IV, see appendix D);
* Vaccination with live vaccines within 28 days prior to registration;
* Use of any other experimental drug or therapy within 28 days prior to registration
* Major surgery within 28 days prior to registration;
* Steroid therapy within 10 days prior to registration, with the exception of inhaled steroids for asthma, topical steroids, steroids up to 20 mg of dose equivalents of prednisolone daily to control autoimmune phenomenon's, or replacement/stress corticosteroids;
* Pregnant women and nursing mothers;
* Fertile men or women of childbearing potential unless: (1) surgically sterile or ≥ 2 years after the onset of menopause, and/or (2) willing to use a highly effective contraceptive method such as oral contraceptives, intrauterine device, sexual abstinence or barrier method of contraception in conjunction with spermicidal jelly during study treatment and in female patients for 3 months after end of induction treatment and 18 months after end of treatment with obinutuzumab and male patients for 6 months after end of treatment;
* Current participation in other clinical trial;
* Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

Primary outcomes:
measure: BM uMRD CR 3 months after end of intensification with ibrutinib/obinutuzumab in patients who were not in CR or who had detectable MRD on combination ibrutinib and venetoclax.
timeFrame: 5 years
Secondary outcomes:
measure: BM uMRD CR 9 months after registration 2 in all subjects
timeFrame: 5 years
measure: Best BM MRD level on protocol
timeFrame: 5 years
measure: MRD level in BM and PB at different time points on protocol and in follow up
timeFrame: 5 years
measure: Best response by IWCLL on protocol
timeFrame: 5 years
measure: Response by IWCLL at different time points
timeFrame: 5 years
measure: Response by Deauville criteria on PET scan at different time points
timeFrame: 5 years
measure: Progression free survival (PFS), defined as time from registration 1 and from registration 2 to progression or death from any cause, whichever comes first
timeFrame: 5 years
measure: Event free survival (EFS), defined as time from registration 1 and from registration 2 to start new CLL treatment, progression or death, whichever comes first
timeFrame: 5 years
measure: Overall survival (OS), defined as time from registration 1 and from registration 2 to death from any cause
timeFrame: 5 years
measure: Treatment free interval (TFI), defined as date of last protocol treatment to start date of first CLL treatment off protocol, or death from any cause whichever comes first
timeFrame: 5 years
measure: Predictive value of prognostic markers at diagnosis on uMRD and ORR by IWCLL and Deauville criteria at end of ibrutinib/venetoclax and ibrutinib/obinutuzumab
timeFrame: 5 years
measure: CTCAE grade ≥2 toxicities
timeFrame: 5 years
measure: IWCLL hematological grade ≥2toxicities
timeFrame: 5 years
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: DK-Aalborg-AALBORGUH
city: Herlev
country: Denmark
facility: DK-Herlev-HERLEV
city: Odense
country: Denmark
facility: DK-Odense-OUH
city: Roskilde
country: Denmark
facility: DK-Roskilde-ROSKILDE
city: Almere
country: Netherlands
facility: NL-Almere-FLEVOZIEKENHUIS
city: Amersfoort
country: Netherlands
facility: NL-Amersfoort-MEANDERMC
city: Amsterdam
country: Netherlands
facility: NL-Amsterdam-AMC
city: Amsterdam
country: Netherlands
facility: NL-Amsterdam-VUMC
city: Den Haag
country: Netherlands
facility: NL-Den Haag-HAGA
city: Den Haag
country: Netherlands
facility: NL-Den Haag-HMCWESTEINDE
city: Dordrecht
country: Netherlands
facility: NL-Dordrecht-ASZ
city: Ede
country: Netherlands
facility: NL-Ede-ZGV
city: Eindhoven
country: Netherlands
facility: NL-Eindhoven-CATHARINA
city: Enschede
country: Netherlands
facility: NL-Enschede-MST
city: Gouda
country: Netherlands
facility: NL-Gouda-GROENEHART
city: Groningen
country: Netherlands
facility: NL-Groningen-UMCG
city: Hilversum
country: Netherlands
facility: NL-Hilversum-TERGOOI
city: Hoofddorp
country: Netherlands
facility: NL-Hoofddorp-SPAARNEGASTHUIS
city: Roermond
country: Netherlands
facility: NL-Roermond-LZR
city: Rotterdam
country: Netherlands
facility: NL-Rotterdam-IKAZIA
city: Sittard
country: Netherlands
facility: NL-Sittard-Geleen-ZUYDERLAND
city: Sneek
country: Netherlands
facility: NL-Sneek-ANTONIUSSNEEK
city: Terneuzen
country: Netherlands
facility: NL-Terneuzen-ZORGSAAM
city: Tilburg
country: Netherlands
facility: NL-Tilburg-ETZ
city: Uden
country: Netherlands
facility: NL-Uden-BERNHOVEN
city: Utrecht
country: Netherlands
facility: NL-Utrecht-UMCUTRECHT
city: Zwolle
country: Netherlands
facility: NL-Zwolle-ISALA
Study officials:
affiliation: Amsterdam UMC
name: Arnon Kater, PhD
role: PRINCIPAL_INVESTIGATOR
References: